ライフサイエンスコーパス: pyrazinamide

1 standard regimen of rifampin, isoniazid, and pyrazinamide.

2 standard regimen of isoniazid, rifampin, and pyrazinamide.

3 t this enzyme is not the immediate target of pyrazinamide.

4 ranging from 0.5 to 16 times the potency of pyrazinamide.

5 tis pncA or pzaA conferred susceptibility to pyrazinamide.

6 imen of isoniazid, rifampin, ethambutol, and pyrazinamide.

7 and particularly with the regimen containing pyrazinamide.

8 nsasii, organisms usually not susceptible to pyrazinamide.

9 d 3-drug regimen of isoniazid, rifampin, and pyrazinamide.

10 s that are likely to be effective as well as pyrazinamide.

11 previously associated with susceptibility to pyrazinamide.

12 ted source for ethambutol, streptomycin, and pyrazinamide.

13 eptible to orally administered isoniazid and pyrazinamide.

14 ne and compared with Bactec MGIT results for pyrazinamide.

15 to 0.86); and with isoniazid, rifampin, and pyrazinamide, 0.51 (0.24 to 1.08).

16 poB L452P [rifampicin]; pncA 1 bp insertion [pyrazinamide]; 1984 [95% HPD: 1974-1992]) and 10 y (rpoB

17 months (n = 792) or rifampin, 600 mg/d, and pyrazinamide, 20 mg/kg per day, for 2 months (n = 791).

18 -term outcome, by rank of importance, were a pyrazinamide 24-hour area under the concentration-time c

19 h isoniazid and rifampin (ie, MDR TB), 2.2%; pyrazinamide, 3.0%; streptomycin, 6.2%; and ethambutol h

20 terium tuberculosis, the PZA analog 5-chloro-pyrazinamide (5-Cl-PZA) displays a broader range of anti

21 in; 258 bp), katG (isoniazid; 205 bp), pncA (pyrazinamide; 579 bp); rpsL (streptomycin; 196 bp), and

22 Of patients assigned to rifampin and pyrazinamide, 80% completed the regimen compared with 69

23 hs of ethambutol, isoniazid, rifampicin, and pyrazinamide administered daily followed by 4 months of

24 nds which are both 100-fold more active than pyrazinamide against M. tuberculosis and possess a serum

25 Inclusion of pyrazinamide (aHR 2.00, 95% CI 1.65-2.41) or more drugs

26 hylaxis regimens of isoniazid, rifampin, and pyrazinamide alone or in combination.

27 19 patients (2.4%) assigned to rifampin and pyrazinamide and 26 (3.3%) assigned to isoniazid develop

28 llin, rifampicin, isoniazid, ethambutol, and pyrazinamide and also screen for substitute pharmaceutic

29 parameters, including natural resistance to pyrazinamide and defective pyrazinamidase (PZase) activi

30 o rifampin, fluoroquinolones, isoniazid, and pyrazinamide and enable the selection of the most approp

31 n and isoniazid for 6 months reinforced with pyrazinamide and ethambutol in the first 2 months, given

32 Inclusion of pyrazinamide and ethambutol in the regimen (when suscept

33 ic, and toxicodynamic studies are needed for pyrazinamide and ethionamide.

34 nd South Africa to investigate resistance to pyrazinamide and fluoroquinolones among patients with tu

35 Pyrazinamide and fluoroquinolones are essential antitube

36 nce is limited on the performance of DST for pyrazinamide and second-line drugs.

37 al (isoniazid) and sterilizing (rifampin and pyrazinamide), and ethambutol to help prevent the emerge

38 g/kg rifampicin, 5 mg/kg isoniazid, 25 mg/kg pyrazinamide, and 15-20 mg/kg ethambutol).

39 regimen: 2 mo of daily rifampin, isoniazid, pyrazinamide, and clofazimine followed by 2 mo of rifamp

40 pervision with 2 mo of rifabutin, isoniazid, pyrazinamide, and ethambutol (given daily, thrice-weekly

41 e treated with regimens containing rifampin, pyrazinamide, and ethambutol +/- a FQ for a median of 9.

42 nt, i.e., 2 mo of daily rifampin, isoniazid, pyrazinamide, and ethambutol followed by 4 mo of rifampi

43 up of patients received isoniazid, rifampin, pyrazinamide, and ethambutol for 8 weeks, followed by 18

44 supervised therapy with isoniazid, rifampin, pyrazinamide, and ethambutol thrice weekly for 8 wk, fol

45 In all patients isoniazid, pyrazinamide, and ethambutol were added in standard dose

46 icidal effect rates for isoniazid, rifampin, pyrazinamide, and ethambutol were the same in the HFS-TB

47 rst line antibiotics (isoniazid, rifampicin, pyrazinamide, and ethambutol) is efficient to treat most

48 F), isoniazid [isonicotinylhydrazine (INH)], pyrazinamide, and ethambutol, among other drug therapies

49 regimen (2 months of isoniazid, rifampicin, pyrazinamide, and ethambutol, followed by 6 months of is

50 lates were sensitive to isoniazid, rifampin, pyrazinamide, and ethambutol.

51 r 8 weeks (intensive phase), with isoniazid, pyrazinamide, and ethambutol.

52 r 8 weeks (intensive phase), with isoniazid, pyrazinamide, and ethambutol.

53 arms (63 to rifampicin 35 mg/kg, isoniazid, pyrazinamide, and ethambutol; 59 to rifampicin 10 mg/kg,

54 SQ109; 63 to rifampicin 10 mg/kg, isoniazid, pyrazinamide, and moxifloxacin; and 123 to the control a

55 tiple drugs including isoniazid, ethambutol, pyrazinamide, and rifampin increased from 4.3% to 46% of

56 DST for ethambutol, pyrazinamide, and second-line tuberculosis drugs appears

57 SQ109; 57 to rifampicin 20 mg/kg, isoniazid, pyrazinamide, and SQ109; 63 to rifampicin 10 mg/kg, ison

58 re high, whereas the results for ethambutol, pyrazinamide, and streptomycin resistance were more vari

59 ed odds of treatment success for ethambutol, pyrazinamide, and the group 4 drugs ranged from 1.7 to 2

60 Rifampin and pyrazinamide are recommended for treatment of latent tub

61 standard regimen of isoniazid, rifampin, and pyrazinamide, based on exponential decline regression.

62 ulosis infection is 2 months of rifampin and pyrazinamide, but some patients have died of hepatitis a

63 ong participants who received rifampicin and pyrazinamide compared with 1.0% (p=0.03) among participa

64 hild variability of isoniazid, rifampin, and pyrazinamide concentrations: 110 (77%) completed therapy

65 However, we found that pyrazinamide-containing MDR-LTBI regimens often resulted

66 tes due to adverse effects in persons taking pyrazinamide-containing regimens.

67 of 380 participants assigned rifampicin and pyrazinamide (Cox model rate ratio 1.3 [95% CI 0.7-2.7])

68 d in alternate weeks to receive rifampin and pyrazinamide daily for 2 months (n = 307) or isoniazid d

69 ee months (556), or isoniazid, rifampin, and pyrazinamide daily for three months (462).

70 207 (7.7%) patients assigned to rifampin and pyrazinamide developed grade 3 or 4 hepatotoxicity compa

71 of moxifloxacin to isoniazid, rifampin, and pyrazinamide did not affect 2-mo sputum culture status b

72 alyze the essentiality of both isoniazid and pyrazinamide during the first 14 d of therapy.

73 therapy in the mouse model, whereas omitting pyrazinamide during the first 14 d was detrimental.

74 hat the key sterilizing drugs rifampicin and pyrazinamide efficiently penetrate the sites of TB infec

75 2 months of four-drug (isoniazid, rifampin, pyrazinamide, ethambutol) treatment (induction phase) we

76 estimated the association of DST results for pyrazinamide, ethambutol, and second-line drugs with tre

77 valid drug susceptibility testing (DST) for pyrazinamide, ethambutol, and second-line tuberculosis d

78 onth daily combinations of moxifloxacin with pyrazinamide, ethionamide, or ethambutol were more activ

79 and rifampin for 3 months, and rifampin and pyrazinamide for 2 months had similar results: 6.2- to 8

80 ntive therapy for 6 months or rifampicin and pyrazinamide for 2 months provided similar overall prote

81 for 24 weeks or twice weekly rifampicin and pyrazinamide for 8 weeks.

82 efficacy of isoniazid versus rifampicin with pyrazinamide for prevention of tuberculosis in HIV-1-pos

83 of isoniazid with 2 months of rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1-ser

84 th rifampin, or treatment with rifampin plus pyrazinamide for those with a positive test result.

85 cts received either rifampin, isoniazid, and pyrazinamide for two months, followed by rifampin and is

86 tion was slightly higher in the rifampin and pyrazinamide group (P = .01).

87 toxic adverse events was 20% in the rifampin-pyrazinamide group and 16% in the isoniazid group.

88 nes-rpoB (rifampin), katG (isoniazid), pncA (pyrazinamide), gyrA (ofloxacin/fluoroquinolone), and rrs

89 Antagonism between isoniazid and pyrazinamide has been demonstrated in a TB treatment mou

90 nent of the mycobacterial cell envelope, and pyrazinamide has no known target.

91 drugs, including isoniazid, ethambutol, and pyrazinamide have also recently been defined.

92 hesis was irreversibly inhibited by 5-chloro-pyrazinamide in a time-dependent fashion.

93 at a susceptibility breakpoint of 100 mug/ml pyrazinamide in MGIT within a cohort of isolates from So

94 an tuberculosis and that the full benefit of pyrazinamide in this regimen may be realized after just

95 hundred fourteen patients received rifampin/pyrazinamide in Wake County, North Carolina, between Dec

96 nd their mechanisms of action.The antibiotic pyrazinamide is central to tuberculosis treatment regime

97 nts, a daily 2-month regimen of rifampin and pyrazinamide is similar in safety and efficacy to a dail

98 A alleles that confer clinical resistance to pyrazinamide is unknown.

99 of patients had Cmax of rifampicin <8 mg/L, pyrazinamide <35 mg/L, and isoniazid <3 mg/L.

100 that the use of rifampin, moxifloxacin, and pyrazinamide may substantially shorten the duration of t

101 st 4 months with rifampin, moxifloxacin, and pyrazinamide, mice treated with rifampin, isoniazid, and

102 g pretomanid (formerly known as PA-824), and pyrazinamide (MPa100Z regimen); moxifloxacin, 200 mg pre

103 gimen); moxifloxacin, 200 mg pretomanid, and pyrazinamide (MPa200Z regimen); or the current standard

104 d elsewhere in BALB/c mice, moxifloxacin and pyrazinamide (MZ) combination was not bactericidal beyon

105 t to capreomycin, rifampin, isoniazid (INH), pyrazinamide, or streptomycin (STR), 4 were resistant to

106 redictors of therapy failure or death were a pyrazinamide peak concentration <38.10 mg/L and rifampin

107 ven with oral 5 mg/kg isoniazid and 25 mg/kg pyrazinamide per day for 12 weeks, followed by 14 weeks

108 pled to determine rifampicin, isoniazid, and pyrazinamide plasma concentrations after 7-8 weeks of th

109 onamide, or ethambutol were more active than pyrazinamide plus ethambutol, a regimen recommended for

110 Testing for susceptibility to pyrazinamide (PZA) and analysis of the pncA gene sequenc

111 is complex were tested for susceptibility to pyrazinamide (PZA) by the ESP (Trek Diagnostic Systems,

112 utol (EMB) (collectively known as SIRE), and pyrazinamide (PZA) drug susceptibility testing was perfo

113 utics isoniazid (INH), rifampicin (RIF), and pyrazinamide (PZA) have been labeled with carbon-11 and

114 Pyrazinamide (PZA) is a first line anti-tubercular drug

115 Pyrazinamide (PZA) is a first-line tuberculosis drug tha

116 Pyrazinamide (PZA) is a key antituberculosis drug, yet n

117 Pyrazinamide (PZA) is an important antituberculosis drug

118 Pyrazinamide (PZA) is an important first-line drug in al

119 Pyrazinamide (PZA) is an integral component of the short

120 Pyrazinamide (PZA) is essential in tuberculosis treatmen

121 uberculosis biochemically, but resistance to pyrazinamide (PZA) rendered that diagnosis suspect.

122 erformance liquid chromatography to identify pyrazinamide (PZA) resistance in Mycobacterium tuberculo

123 mitations of common tests used for detecting pyrazinamide (PZA) resistance in Mycobacterium tuberculo

124 bacterium tuberculosis complex that have any pyrazinamide (PZA) resistance, using a confirmatory test

125 Isoniazid (INH), 2 quinolones, and pyrazinamide (PZA) showed intermediate levels of activit

126 ypic determination of the rifampin (RMP) and pyrazinamide (PZA) susceptibilities of M. tuberculosis i

127 A new agar medium to perform pyrazinamide (PZA) susceptibility testing with Mycobacte

128 azinamidase (PZAase)/nicotinamidase converts pyrazinamide (PZA) to ammonia and pyrazinoic acid, which

129 six months by the indispensable addition of pyrazinamide (PZA) to the drug regimen that includes iso

130 Here, we identify pyrazinamide (PZA), a clinical drug used to treat tuberc

131 earances of isoniazid (INH), rifampin (RIF), pyrazinamide (PZA), and ethambutol (EMB).

132 al activity of DCP was comparable to that of pyrazinamide (PZA), one of the first-line antituberculos

133 (INH), rifampin (RIF), ethambutol (EMB), and pyrazinamide (PZA), were determined.

134 Naturally pyrazinamide (PZA)-resistant Mycobacterium bovis and acq

135 rally resistant to the antituberculosis drug pyrazinamide (PZA).

136 (INH), rifampin (RMP), ethambutol (EMB), and pyrazinamide (PZA).

137 rument using the 21-day protocol (Bactec 960 pyrazinamide [PZA] protocol).

138 ) TB identification; and 75.0% and 98.1% for pyrazinamide(r) TB identification.

139 n-resistant (rifampin(r)), isoniazid(r), and pyrazinamide(r) TB.

140 e combination of moxifloxacin, rifampin, and pyrazinamide reduced the time needed to eradicate Mycoba

141 The rifampin/pyrazinamide regimen for latent tuberculosis infection m

142 The rifampin plus pyrazinamide regimen was more likely than the isoniazid

143 3 [CrI, 0.36 to 0.78]), rifampicin-isoniazid-pyrazinamide regimens (OR, 0.35 [CrI, 0.19 to 0.61]), an

144 R, 0.35 [CrI, 0.19 to 0.61]), and rifampicin-pyrazinamide regimens (OR, 0.53 [CrI, 0.33 to 0.84]) wer

145 , mice treated with rifampin, isoniazid, and pyrazinamide required 6 months of treatment before no re

146 We then screened it for pyrazinamide resistance both in vitro and in an infected

147 Pyrazinamide resistance was assessed in 4972 patients.

148 In all settings, pyrazinamide resistance was significantly associated wit

149 Although pyrazinamide resistance was significantly associated wit

150 tient to identification of BCG, detection of pyrazinamide resistance, and phylogenetic placement was

151 ne DNA-sequencing method to rapidly identify pyrazinamide resistance-causing mutations in GenoLyse-tr

152 colleagues characterise the genetic basis of pyrazinamide resistance.

153 of PZAase activity is the major mechanism of pyrazinamide-resistance by M. tuberculosis.

154 3-month regimen of isoniazid, rifampin, and pyrazinamide resulted in fewer clinical benefits and was

155 are treated with antibiotics (isoniazid and pyrazinamide), resulting in no detectable bacilli by org

156 mutations on line probe assay and performed pyrazinamide sequencing.

157 ice treated with rifampin, moxifloxacin, and pyrazinamide, similar efficacy was noted whether pyrazin

158 butol; 59 to rifampicin 10 mg/kg, isoniazid, pyrazinamide, SQ109; 57 to rifampicin 20 mg/kg, isoniazi

159 daily (5 d/wk) moxifloxacin, ethambutol, and pyrazinamide, supplemented with amikacin during the firs

160 s could not be established for nicotinamide (pyrazinamide surrogate), prothionamide, or ethionamide,

161 Methods for testing pyrazinamide susceptibility are difficult and rarely per

162 obacterium tuberculosis pncA gene allows for pyrazinamide susceptibility testing.

163 esults suggest that optimizing the dosing of pyrazinamide, the injectables, and isoniazid for drug-re

164 reatment by the introduction of rifampin and pyrazinamide, the two most potent sterilizing drugs, int

165 71(+) BM-MSCs after 90 days of isoniazid and pyrazinamide therapy that rendered animal's lung noninfe

166 tinic acid, PncA also hydrolyzes the prodrug pyrazinamide to generate the active form of the drug, py

167 e antimycobacterial activity associated with pyrazinamide to include M. avium and M. kansasii, organi

168 Pyrazinamide use for initial treatment for children has

169 a combination of rifampin, moxifloxacin, and pyrazinamide was able to shorten the time to negative lu

170 zinamide, similar efficacy was noted whether pyrazinamide was administered for 1 month, 2 months, or

171 Resistance to pyrazinamide was assessed by gene sequencing with the de

172 Rifampin/pyrazinamide was associated with a significantly higher

173 A 2-month regimen of rifampin and pyrazinamide was associated with an increased risk for g

174 Pyrazinamide was shown to sterilize only in the intensiv

175 Rifampin plus pyrazinamide was the preferred strategy for treating lat

176 erapy (rifampicin, isoniazid, ethambutol and pyrazinamide) was initiated upon Mycobacterium confirmat

177 combination of moxifloxacin, pretomanid, and pyrazinamide, was safe, well tolerated, and showed super

178 netic parameters of isoniazid, rifampin, and pyrazinamide were identified for each patient.

179 py is dependent on the use of the antibiotic pyrazinamide, which is being threatened by emerging drug

180 ation-dependent antagonism with rifampin and pyrazinamide, with an adjusted odds ratio for therapy fa

181 Whether pyrazinamide (Z) contributes sterilizing activity beyond

182 ages added to a regimen of isoniazid (H) and pyrazinamide (Z) was assessed.

183 omanid (Pa), combined with an existing drug, pyrazinamide (Z), and a repurposed drug, clofazimine (C)

184 floxacin [M], isoniazid [H], rifampicin [R], pyrazinamide [Z], ethambutol [E]) or the control regimen